Novo Nordisk Stock Sinks After 2026 Guidance Flags 5%–13% Sales Drop

Novo Nordisk A/S unexpectedly pre-released its 2026 outlook late Tuesday, projecting a sales decline of 5% to 13%. As of 10:23 AM EST on February 4, 2026, shares were off about 18% in Copenhagen and the ADS traded at $47.60, down 5.37%. Analysts cited U.S. pricing pressure, patent expiries, and competition as key headwinds.